gilead sciences

Gilead Sciences Announced Licensing of Portfolio of HIV Antibodies

Gilead Sciences Announced Licensing of Portfolio of HIV Antibodies

Gilead Sciences, Inc. (NASDAQ: GILD) announced Thursday that it has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074. These inve..

Gilead Shares Fall After Hepatitis C treatment Sales Plunge

Gilead Shares Fall After Hepatitis C treatment Sales Plunge

Gilead Sciences Inc. (NASDAQ: GILD) reported its first quarter financial results after market close on Tuesday and missed analysts estimates. Shares fell by 7 percent after the opening bell on Wednesday.For the first quarter, Gilead reported revenue..